Progresses in Hematopoietic Stem Cell Transplantation and Cellular Therapies

A special issue of Transplantology (ISSN 2673-3943). This special issue belongs to the section "Artificial Organs, Stem Cells and Xenotransplantation".

Deadline for manuscript submissions: closed (15 October 2021) | Viewed by 13412

Special Issue Editors


E-Mail Website
Guest Editor
Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Interests: acute leukemias; stem cell transplanation; CAR-T therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Fundeni Clinical Institute, Bucharest, Romania
Interests: bench-to-medside; experimental therapeutics; stem cell transplantation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania
Interests: hematological malignancies; hematopoiesis; stem cell transplantation; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hematological malignancies are considered to be one of the most important causes of mortality and morbidity in the modern world. Still, important progress has been made in the last decade due to breackthroughs in hematopoietic stem cell transplantation and cellular therapies. The results of recent studies show that a promising road toward state-of-the-art treatment for the hematology patient, turning the diagnosis of leukemia or lymphoma into a curable disease, has now only already begun with recent advances in hematopoietic stem cell transplantation and immunotherapy, but is now progressing forward. The prospect of providing a definitive alternative therapy for various malignancies, rather than conventional chemotherapy management, is indeed clinically, socially, and economically attractive, due to the huge medical, social, and economic burden that a malignancy imposes. The current joint Special Issue aims to present a modern approach in recent advances in stem cell transplantation for the hematological patient, with a special emphasis on progress in conditioning chemotehrapy and cellular therapies.

The present call for manuscripts is addressed at healthcare professionals that diagnose, treat, and do research in stem cell transplantation, with a special emphasis on state-of-the-art therapeutics and novel, emerging drugs and novel cellular therapies. Comprehensive reviews, as well as research (be it basic, translational or clinical research) or even interesting case series or case reports are welcomed, with the goal to present new approaches in the clinical management of the patient, patients diagnosed with a malignancy and undergoing a stem cell transplantation, approaches that may be newly approved drugs, clinical trials on the pipeline or even promising future therapeutic alternatives.

Dr. Anca Colita
Dr. Alina Tanase
Dr. Ciprian Tomuleasa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Transplantology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • experimental therapeutics
  • translational medicine
  • epigenetics
  • preclinical data
  • cancer

Related Special Issue

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

17 pages, 1340 KiB  
Article
HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis
by Massimo Berger, Marta Barone, Fabrizio Carnevale-Schianca, Marco De Gobbi, Paolo Nicoli, Daniela Caravelli, Daniela Cilloni, Luca Paruzzo, Manuela Spadea, Katia Mareschi, Massimo Aglietta and Franca Fagioli
Transplantology 2022, 3(1), 51-67; https://doi.org/10.3390/transplantology3010006 - 8 Feb 2022
Viewed by 2849
Abstract
HSCT from an unrelated HLA-mismatched donor (MMUD) is one of the alternatives where an HLA-matched donor is not found. The aim of this study was to compare GvHD prophylaxis with anti-thymocyte globulin (ATG) vs. post-transplant cyclophosphamide (PT-Cy). Thirty-nine adult patients were uniformly treated [...] Read more.
HSCT from an unrelated HLA-mismatched donor (MMUD) is one of the alternatives where an HLA-matched donor is not found. The aim of this study was to compare GvHD prophylaxis with anti-thymocyte globulin (ATG) vs. post-transplant cyclophosphamide (PT-Cy). Thirty-nine adult patients were uniformly treated with rabbit ATG-Cy-A-MTX and peripheral blood stem cell (PBSC) and 40 adult patients with PT-Cy-MMF-tacrolimus and PBSC. This retrospective study was registered at ClinicalTrials.gov NCT04598789. Three-year overall survival was 42% vs. 64% for ATG and PT-Cy (p < 0.0005), three-year treatment-related mortality (TRM) was 36% vs. 8% (p = 0.0033) and the three-year relapse incidence (RI) was 15% vs. 28% (p = NS), respectively. The incidences of day-100 GvHD graded II–IV and III–IV were 39% vs. 7% (p = 0.0006) and 11% vs. 0% (p = 0.04), respectively, whereas the three-year cGvHD incidences were 48% vs. 13% (p = 0.0005), respectively. We were able to show how PT-Cy can reduce the incidence of GvHDs and TRM in adults, but relapse remains an issue. Full article
Show Figures

Figure 1

Review

Jump to: Research, Other

16 pages, 1012 KiB  
Review
Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma
by Sonja Genadieva Stavrik and Anna Sureda
Transplantology 2021, 2(4), 396-411; https://doi.org/10.3390/transplantology2040038 - 3 Oct 2021
Viewed by 3210
Abstract
Although the majority of patients with Hodgkin lymphoma (HL) are cured with initial therapy, in 85–90% of early stage and 70–80% of advanced-stage disease cases, relapse remains a major problem. Autologous stem-cell transplantation (auto-HCT) after salvage chemotherapy is currently considered to be the [...] Read more.
Although the majority of patients with Hodgkin lymphoma (HL) are cured with initial therapy, in 85–90% of early stage and 70–80% of advanced-stage disease cases, relapse remains a major problem. Autologous stem-cell transplantation (auto-HCT) after salvage chemotherapy is currently considered to be the standard of care for patients who relapse after first-line chemotherapy or for whom first-line treatment fails. The curative capacity of auto-HCT has been improving with the introduction of new drug-based salvage strategies and consolidation strategies after auto-HCT. Allogeneic stem-cell transplantation (allo-HCT) represents a reasonable treatment option for young patients who relapse or progress after auto-HCT and have chemosensitive disease at the time of transplantation. Allo-HCT is a valid treatment strategy for patients with relapse/refractory HL (r/r HL) because the results have improved over time, mainly with the safe combination of allo-HCT and new drugs. Bearing in mind that outcomes after haploidentical stem-cell transplantation (haplo-HCT) are comparable with those for matched sibling donors and matched unrelated donors, haplo-HCT is now the preferred alternative donor source for patients with r/r HL without a donor or when there is urgency to find a donor if a matched related donor is not present. The development of new drugs such as anti-CD 30 monoclonal antibodies and checkpoint inhibitors (CPI) for relapsed or refractory HL has demonstrated high response rates and durable remissions, and challenged the role and timing of HCT. The treatment of patients with HL who develop disease recurrence or progression after allo-HCT remains a real challenge and an unmet need. Full article
Show Figures

Figure 1

14 pages, 266 KiB  
Review
Management of Herpesvirus Infections in Hematopoietic Cell Transplant Recipients
by Jan Styczynski
Transplantology 2021, 2(1), 8-21; https://doi.org/10.3390/transplantology2010002 - 6 Jan 2021
Cited by 6 | Viewed by 3760
Abstract
Following primary infection, herpesviruses establish latency in infected individuals in the host cells and may reactivate upon external stimuli and during periods of immunosuppression. The objective of this paper was to the present current strategies on preventive and therapeutic management of infections with [...] Read more.
Following primary infection, herpesviruses establish latency in infected individuals in the host cells and may reactivate upon external stimuli and during periods of immunosuppression. The objective of this paper was to the present current strategies on preventive and therapeutic management of infections with herpesviruses in recipients of hematopoietic cell transplantation. Strategies of antiviral management include prophylaxis, pre-emptive treatment and targeted treatment. Empirical therapy is not used in antiviral strategies. Prophylaxis can be done at universal (preventive strategy) and specific level. Universal prophylaxis includes non-pharmacologic methods of prevention of infection or reactivation. Risk-adapted specific prophylaxis includes use of specific antivirals or cellular therapy or other specific methods in order to prevent specific infection, in high-risk groups. Pre-emptive therapy means use of therapeutic approaches in asymptomatic infection, detected by a screening assay. Targeted therapy is used in established specific viral end-organ infections. The following sections of the paper refer to prophylaxis and treatment strategies, respectively, against CMV, EBV, HSV, VZV, HHV-6, HHV-7, and HHV-8 after allogeneic hematopoietic cell transplantation. Full article

Other

Jump to: Research, Review

9 pages, 2887 KiB  
Case Report
Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation
by Håkon Reikvam, Tor Henrik Anderson Tvedt, Silje Johansen, Hege Aase Setran and Roald Flesland Havre
Transplantology 2020, 1(2), 102-110; https://doi.org/10.3390/transplantology1020010 - 17 Nov 2020
Viewed by 2659
Abstract
Gastrointestinal graft-versus-host disease (GVHD) and cytomegalovirus (CMV) disease are common complications occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and contribute to a high degree of morbidity and mortality associated with allo-HSCT. Herein, we present a patient with severe intestinal GVHD complicated by [...] Read more.
Gastrointestinal graft-versus-host disease (GVHD) and cytomegalovirus (CMV) disease are common complications occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and contribute to a high degree of morbidity and mortality associated with allo-HSCT. Herein, we present a patient with severe intestinal GVHD complicated by recurring CMV enteritis, which overall resulted in severe terminal ileum stenosis. The patient underwent laparoscopic ileocecal resection that significantly reduced symptoms and possibly prevented the development of fulminant ileus. Surgical treatment is rarely used in the treatment of gastrointestinal GVHD; however, the current patient history illustrates that patients with inadequate symptom control and severe inflammatory bowel stenosis can be successfully managed with surgery. We also review published case reports on surgical treatment for severe gastrointestinal GVHD. Full article
Show Figures

Figure 1

Back to TopTop